Leptomeningeal Metastases of Breast Cancer: Toward New Therapies

Abstract

Leptomeningeal metastases (LM) are growths of breast cancer in the linings of the brain and spinal cord and/or in the cerebrospinal fluid (CSF). LM represent 11-20 percent of central nervous system (CNS) metastases. They are prevalent in younger patients. LM occur in all subclasses of breast cancer and are currently treated with intrathecal (IT) methotrexate or liposomal cytarabine or radiation therapy. Although 68 percent of patients initially responded to chemotherapy treatment, median overall survival was 18 weeks, resulting from LM progression. Severe complications arise from LM. There is an urgent need for research into this devastating form of breast cancer progression to identify new potential preventives and treatments. We have now derived three models for colonization of the leptomeninges and spinal cord from an intrathecal injection. We have preclinical LM prevention experiments planned.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2022
Accession Number
AD1193686

Entities

People

  • Patricia Steeg

Organizations

  • Geneva Foundation

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Biomedical Research
  • Blood Cancers
  • Blood-Brain Barrier
  • Brain
  • Breast Cancer
  • Cancer
  • Carcinoma
  • Cell Line
  • Cells
  • Central Nervous System
  • Diseases
  • Medical Personnel
  • Meninges
  • Neoplasms
  • Nervous System
  • Oncology
  • Radiation
  • Spinal Cord
  • Therapy

Fields of Study

  • Medicine

Readers

  • Cardiovascular Physiology
  • Oncology
  • Oncology (Cancer Research).